These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 2571965

  • 1. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 2. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI.
    Nature; 1989 May 18; 339(6221):230-1. PubMed ID: 2654648
    [Abstract] [Full Text] [Related]

  • 3. The role of the neu oncogene product in cell transformation and normal development.
    Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen J, Hamuro J, Weiner DB, Greene MI.
    Princess Takamatsu Symp; 1988 May 18; 19():45-57. PubMed ID: 2908355
    [Abstract] [Full Text] [Related]

  • 4. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L, Sistonen L, Koskinen P, Lehväslaiho H, Di Renzo MF, Comoglio PM, Alitalo K.
    J Cell Biochem; 1991 Jan 18; 45(1):69-81. PubMed ID: 1706346
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Expression of the neu proto-oncogene by Schwann cells during peripheral nerve development and Wallerian degeneration.
    Cohen JA, Yachnis AT, Arai M, Davis JG, Scherer SS.
    J Neurosci Res; 1992 Apr 18; 31(4):622-34. PubMed ID: 1374476
    [Abstract] [Full Text] [Related]

  • 10. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
    Hong RL, Spohn WH, Hung MC.
    Clin Cancer Res; 1999 Jul 18; 5(7):1884-91. PubMed ID: 10430096
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
    Burke CL, Lemmon MA, Coren BA, Engelman DM, Stern DF.
    Oncogene; 1997 Feb 13; 14(6):687-96. PubMed ID: 9038376
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
    Bosch E, Cherwinski H, Peterson D, McMahon M.
    Oncogene; 1997 Aug 28; 15(9):1021-33. PubMed ID: 9285556
    [Abstract] [Full Text] [Related]

  • 16. Tyrosine phosphorylation of Shc proteins and formation of Shc/Grb2 complex correlate to the transformation of NIH3T3 cells mediated by the point-mutation activated neu.
    Xie Y, Li K, Hung MC.
    Oncogene; 1995 Jun 15; 10(12):2409-13. PubMed ID: 7784091
    [Abstract] [Full Text] [Related]

  • 17. Tyrosine phosphorylation at the membrane-microfilament interface: a p185neu-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein.
    Juang SH, Carvajal ME, Whitney M, Liu Y, Carraway CA.
    Oncogene; 1996 Mar 07; 12(5):1033-42. PubMed ID: 8649794
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ligand-independent oncogenic transformation by the EGF receptor requires kinase domain catalytic activity.
    Danielsen AJ, Maihle NJ.
    Exp Cell Res; 2002 Apr 15; 275(1):9-16. PubMed ID: 11925101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.